Top Research Reports for Visa, ServiceNow & Progressive

21.04.25 22:49 Uhr

Werte in diesem Artikel
Aktien

226,00 EUR -9,00 EUR -3,83%

669,70 EUR -17,80 EUR -2,59%

283,80 EUR -9,20 EUR -3,14%

Indizes

PKT PKT

39.187,0 PKT 1.016,6 PKT 2,66%

16.300,4 PKT 429,5 PKT 2,71%

2.545,8 PKT 62,2 PKT 2,50%

5.287,8 PKT 129,6 PKT 2,51%

Monday, April 21, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ServiceNow, Inc. (NOW) and The Progressive Corp. (PGR), as well as two micro-cap stocks The Monarch Cement Co. (MCEM) and Precipio, Inc. (PRPO). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Expect the Unexpected for a New Trading WeekToday's Featured Research ReportsVisa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+20.3% vs. +15.9%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. It expects net revenues to grow by low double-digits in fiscal 2025. Visa is fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value. However, elevated operating expenses pose margin challenges. We expect this metric to rise 7.6% year over year in fiscal 2025. It is witnessing volatile cash volume from the Asia Pacific and U.S. regions. Hence, the stock warrants a cautious stance.(You can read the full research report on Visa here >>>)Shares of ServiceNow have outperformed the Zacks Computers - IT Services industry over the past year (+4.7% vs. -5.1%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation. ServiceNow had 2,109 total customers with more than $1 million in annual contract value (ACV) at the end of the fourth quarter, which represents 14% year-over-year growth in customers. ServiceNow had 19 deals greater than $5 million in net new ACV. It closed 170 deals greater than $1 million net new ACV. Generative Artificial Intelligence (Gen AI) deals continued to gain traction. ServiceNow is extensively leveraging AI and machine learning technologies to boost the potency of its solutions. Pro Plus AI grew 150% sequentially. It is riding on an expanding partner base and acquisitions. However, NOW is suffering from stiff competition and unfavorable forex.(You can read the full research report on ServiceNow here >>>)Progressive’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the past year (+25.9% vs. +23.9%). The company continues to gain on higher premiums, given its compelling product portfolio, leadership position and strength in both Vehicle and Property businesses. Progressive’s focus on becoming a one-stop insurance destination, catering to customers opting for a combination of home and auto insurance, augurs well for the company's growth. Policies in force and retention ratio should remain healthy. Competitive pricing to retain current customers and address customer needs with new offerings should continue to drive policy life expectancy. However, exposure to catastrophe losses induces underwriting volatility. Escalating expenses due to higher losses and settlement expenses remain an overhang on the margin. Its high debt level induces higher interest expense concerns.(You can read the full research report on Progressive here >>>)Shares of Monarch Cement have outperformed the Zacks Building Products - Concrete and Aggregates industry over the past year (+29.7% vs. -12.2%). This microcap company with market capitalization of $856.63 million offers a compelling case for long-term investors with steady fiscal 2024 growth, driven by effective pricing that offset volume declines. Net sales rose 2% year over year to $268.1 million, with gross profit up 6.7% and cement margins expanding to 52.4%. Strong internal cash generation of $73.6 million supported consistent dividends, including a $2.17 special payout. Retained earnings climbed 13.1% to $368.5 million, boosting equity to $403.9 million and reinforcing capital strength. Monarch Cement remains debt-free, with $48.8 million in cash and access to $15 million in credit. Its regional footprint and dual revenue streams add diversification, while long-term raw material reserves support sustainable production. A new JV enhances downstream exposure and capital flexibility. Monarch Cement’s brand, balance sheet, and strategic initiatives underscore its durability and income appeal.(You can read the full research report on Monarch Cement here >>>)Precipio’s shares have outperformed the Zacks Medical Info Systems industry over the year-to-date period (+11.7% vs. -5.2%). This microcap company with a market capitalization of $8.85 million is transitioning from capital preservation to a growth-oriented, self-funded model, driven by its profitable Pathology division, which exceeded its $1.3 million per month breakeven for two straight quarters, and targets a $25 million run-rate by 2025. The Products unit, flat in fourth-quarter 2024, is poised for growth via leadership changes, major client onboarding and a revamped distribution strategy, aiming to double revenue to $5.6 million. Precipio’s strategic execution, disciplined spending, capital-light model and alignment with precision diagnostics trends support long-term potential. Risks include fragile liquidity, execution delays, regulatory shifts, customer concentration and macroeconomic headwinds that could pressure growth and margins. The stock appears undervalued, signaling an entry point for value-oriented investors.(You can read the full research report on Precipio here >>>)Other noteworthy reports we are featuring today include Toyota Motor Corp. (TM), GSK plc (GSK) and Paychex, Inc. (PAYX).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadVisa (V) Rides On Cross Border Volume Growth, Expenses HighGrowing Customer Base Drives ServiceNow's (NOW) ProspectsProgressive's (PGR) Solid Policies in Force Aid, Cat Loss AilFeatured ReportsSurge in Hybrid Adoption Aids Toyota (TM), High Expenses AilPer the Zacks analyst, continued growth in hybrid adoption is likely to boost Toyota's sales. However, high R&D expenses on advanced technologies are likely to limit the near-term margins.GSK (GSK) Specialty Medicines Unit Strong; Vaccines WeakGSK is witnessing increased sales growth of the Specialty Medicines unit. However, slowing sales in the Vaccines unit concerns the Zacks analystPaychex (PAYX) Gains on Flexible Portfolio Despite ExpensesPer the Zacks analyst, Paychex's ability to meet clients' HR and payroll needs through a comprehensive and flexible service portfolio benefits its top line. Rising expenses are concerning.Southwest Airlines (LUV) Rides on Air Travel Demand, Costs AilThe Zacks Analyst likes LUV's revenue management actions, which are likely to boost revenue growth and expand the customer base. However, the rise in labor costs weighs on bottom-line growth.Smart Water Innovation & Buyouts Drive Badger Meter (BMI)Per the Zacks analyst, Badger Meter's performance is driven by its customer-focused innovation, and strategic agility. SmartCover acquisition is paying off early with positive feedback from customers.Amedisys (AMED) Rides on Key Metric, Merger Woes PersistPer the Zacks analyst, Amedisys achieving the Quality of Patient Care star average of 4.18 across all providers, is impressive. Yet, legal hurdles cloud its proposed merger with UnitedHealth Group.Transocean Buoyed by Strong Backlog and UtilizationThe Zacks analyst notes that Transocean's $7.9 billion backlog and near-full fleet utilization boost revenue visibility, but its high debt remains a concern.New UpgradesSolid Demand Across Data Center Market Aid Marvell (MRVL)Per the Zacks Analyst, Marvell is growing on solid momentum in electro-optics products, custom silicon, storage and switch divisions, which are driving the Data Center end-market revenues.Loans, Dealer Enrolments to Support Credit Acceptance (CACC)Per the Zacks analyst, decent loan demand, rising dealer enrollments, a high cash flow-generating business model, and a solid balance sheet will likely aid Credit Acceptance's financials.Advance Technology, Acquisitions Aid Consolidated Water (CWCO)Per the Zacks analyst, Consolidated Water uses most advanced technology for desalination, allowing it to benefit by meeting increasing demand. Strategic acquisitions will boost its performance.New DowngradesAmerican Eagle's (AEO) Soft FY25 View Indicates More TroublesPer the Zacks analyst, American Eagle is expected to face headwinds in fiscal 2025 from consumer trends and macroeconomic climate, despite measures taken to reinforce sales and lower expenses. Soft Comps & Macro Woes Ail Dave & Buster's (PLAY) ProspectsPer the Zacks analyst, Dave & Buster's is likely to be hurt by a drop in comps and store renovation disruptions. Also, an uncertain tariff environment is a concern.Increasing Costs and Forex Woes to Hurt Zebra TechnologiesPer the Zacks analyst, Zebra Technologies is struggling with high operating costs and expenses, which in turn, are hurting the company's bottom line. Forex woes are an added concern.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report Toyota Motor Corporation (TM): Free Stock Analysis Report Paychex, Inc. (PAYX): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report ServiceNow, Inc. (NOW): Free Stock Analysis Report Precipio, Inc. (PRPO): Free Stock Analysis Report The Monarch Cement Co. (MCEM): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Progressive und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Progressive

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Progressive

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Visa Inc.

Wer­bung

Analysen zu Visa Inc.

DatumRatingAnalyst
21.02.2025Visa BuyGoldman Sachs Group Inc.
31.01.2025Visa OutperformRBC Capital Markets
31.01.2025Visa KaufenDZ BANK
31.01.2025Visa BuyUBS AG
31.01.2025Visa BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
21.02.2025Visa BuyGoldman Sachs Group Inc.
31.01.2025Visa OutperformRBC Capital Markets
31.01.2025Visa KaufenDZ BANK
31.01.2025Visa BuyUBS AG
31.01.2025Visa BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
18.05.2018Visa NeutralUBS AG
15.04.2016Visa NeutralCompass Point
24.07.2015Visa HoldTopeka Capital Markets
24.07.2015Visa Mkt PerformFBR Capital
30.01.2015Visa Mkt PerformFBR Capital
DatumRatingAnalyst
01.11.2012Visa sellUBS AG
12.09.2012Visa sellUBS AG
26.07.2012Visa sellUBS AG
09.07.2012Visa sellUBS AG
11.12.2008Visa underperformCowen and Company, LLC

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Visa Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen